To assess whether CLL is indeed a condition per se sufficient to enhance the plasma levels of this protein we monitored the circulating levels of CgA in Eμ-TCL1 mice, a transgenic mouse model of CLL [23]. This evidence concerns the gene CGA and B-cell chronic lymphocytic leukemia.